BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 19264518)

  • 1. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
    Gama A; Alves A; Schmitt F
    Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
    Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
    Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.
    Ramalho LN; Ribeiro-Silva A; Cassali GD; Zucoloto S
    Vet Pathol; 2006 Jul; 43(4):424-9. PubMed ID: 16846983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
    Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
    Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
    Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
    Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptors in canine mammary gland tumours.
    Sobczak-Filipiak M; Malicka E
    Pol J Vet Sci; 2002; 5(1):1-5. PubMed ID: 11944580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p63: a novel myoepithelial cell marker in canine mammary tissues.
    Gama A; Alves A; Gartner F; Schmitt F
    Vet Pathol; 2003 Jul; 40(4):412-20. PubMed ID: 12824513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
    Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
    Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myoepithelial cell layer integrity in canine mammary carcinoma.
    Sánchez-Céspedes R; Millán Y; Guil-Luna S; García-Monterde J; Reymundo C; Espinosa de los Monteros A; Martín de las Mulas J
    J Comp Pathol; 2011 Jul; 145(1):25-30. PubMed ID: 21247585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
    Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD
    Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
    Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
    Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems.
    Pereira PD; Lopes CC; Matos AJ; Cortez PP; Gärtner F; Medeiros R; Lopes C
    J Comp Pathol; 2010; 143(2-3):87-93. PubMed ID: 20153868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the diagnosis and treatment of canine mammary tumours: Immunohistochemical markers as prognostic tools.
    Morris JS
    Vet J; 2010 Apr; 184(1):3-4. PubMed ID: 19713137
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers.
    Kim NH; Lim HY; Im KS; Kim JH; Sur JH
    J Comp Pathol; 2013 May; 148(4):298-306. PubMed ID: 23079102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative activity, apoptosis and expression of oestrogen receptor and Bcl-2 oncoprotein in canine mammary gland tumours.
    Yang WY; Liu CH; Chang CJ; Lee CC; Chang KJ; Lin CT
    J Comp Pathol; 2006 Jan; 134(1):70-9. PubMed ID: 16423573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
    Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
    J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of CD44 adhesion factor in canine mammary carcinomas.
    Madrazo J; García-Fernández RA; García-Iglesias MJ; Durán AJ; Espinosa J; Pérez-Martínez C
    Vet J; 2009 Jun; 180(3):371-6. PubMed ID: 18299241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression.
    Parikh RR; Yang Q; Higgins SA; Haffty BG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):35-42. PubMed ID: 17855007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues.
    Gama A; Gärtner F; Alves A; Schmitt F
    Res Vet Sci; 2009 Dec; 87(3):432-7. PubMed ID: 19464036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.